Innoviva (INVA) Liabilities and Shareholders Equity (2010 - 2026)

Innoviva (INVA) posted Liabilities and Shareholders Equity of $1.8 billion for Q1 2026, up 12.32% on a QoQ basis from $1.6 billion in Q4 2025, and up 46.41% year-over-year from $1.3 billion in Q1 2025.

Innoviva (INVA) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends

Innoviva's Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $1.8 billion for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 46.41% year-over-year to $1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 billion (up 24.39% YoY) and the FY2025 annual result came in at $1.6 billion, up 25.68% from the prior year.
  • Liabilities and Shareholders Equity was $1.8 billion for Q1 2026 at Innoviva, up from $1.6 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.8 billion in Q1 2026 and bottomed at $1.1 billion in Q1 2022.
  • A 5-year average of $1.3 billion and a median of $1.2 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 49.65% — and 2023, when it decreased 10.51%.
  • Innoviva's Liabilities and Shareholders Equity stood at $1.2 billion in 2022, then gained by 0.98% to $1.2 billion in 2023, then gained by 4.63% to $1.3 billion in 2024, then increased by 25.68% to $1.6 billion in 2025, then advanced by 12.32% to $1.8 billion in 2026.
  • Business Quant data shows INVA's Liabilities and Shareholders Equity at $1.8 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.4 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 311.58 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 78.88 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 8.55 Bn
4 NuCana 279.75 Bn 279.75 Bn - 39.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - 811.27 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 10.03 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 2.25 Bn
10 Innoviva 1.57 Bn 969.11 Mn 75.83 Mn 1.84 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.84 Bn
Dec 31, 2025 1.64 Bn
Sep 30, 2025 1.43 Bn
Jun 30, 2025 1.33 Bn
Mar 31, 2025 1.25 Bn
Dec 31, 2024 1.30 Bn
Sep 30, 2024 1.23 Bn
Jun 30, 2024 1.22 Bn
Mar 31, 2024 1.27 Bn
Dec 31, 2023 1.24 Bn
Sep 30, 2023 1.19 Bn
Jun 30, 2023 1.12 Bn
Mar 31, 2023 1.13 Bn
Dec 31, 2022 1.23 Bn
Sep 30, 2022 1.33 Bn
Jun 30, 2022 1.14 Bn
Mar 31, 2022 1.11 Bn
Dec 31, 2021 926.40 Mn
Sep 30, 2021 887.24 Mn
Jun 30, 2021 789.15 Mn